But-3-enoic acid;oxepan-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 英文名称: But-3-enoic acid;oxepan-2-one
• 英文别名: but-3-enoic acid;oxepan-2-one
• 化学式: C10H16O4
• 分子量: 200.23
• InChiKey: MOMYWXPVQREAOJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.75
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Bioresorbable scaffold having sustained drug delivery
  申请人：Scanlon John James

  公开号：US11147696B2

  公开（公告）日：2021-10-19

  A multilayer bioresorbable stent having sustained drug delivery is disclosed herein. The bioresorbable stent releases a therapeutic substance from the body of the bioresorbable stent starting when the bioresorbable stent is implanted within an anatomical lumen and ending when the entire mass of the bioresorbable stent is no longer present within the anatomical lumen. The bioresorbable stent releases the therapeutic substance gradually during the treatment as the mass of the each layer of the bioresorbable stent erodes. Methods of making the therapeutic layers within the bioresorbable sent are further disclosed. Sustained drug delivery reduces the risk of late and very late stent thrombosis.

  本文公开了一种具有持续给药功能的多层生物可吸收支架。该生物可吸收支架从生物可吸收支架的体内释放治疗物质，从生物可吸收支架植入解剖腔开始，到生物可吸收支架的全部质量不再存在于解剖腔内结束。在治疗过程中，生物可吸收支架会随着生物可吸收支架各层质量的侵蚀而逐渐释放治疗物质。还进一步公开了在生物可吸收支架内制作治疗层的方法。持续给药可降低晚期和极晚期支架血栓形成的风险。
• US20140271771A1
  申请人：——

  公开号：US20140271771A1

  公开（公告）日：2014-09-18
• BIORESORBABLE SCAFFOLD HAVING SUSTAINED DRUG DELIVERY
  申请人：Scanlon John James

  公开号：US20190209354A1

  公开（公告）日：2019-07-11

  A multilayer bioresorbable stent having sustained drug delivery is disclosed herein. The bioresorbable stent releases a therapeutic substance from the body of the bioresorbable stent starting when the bioresorbable stent is implanted within an anatomical lumen and ending when the entire mass of the bioresorbable stent is no longer present within the anatomical lumen. The bioresorbable stent releases the therapeutic substance gradually during the treatment as the mass of the each layer of the bioresorbable stent erodes. Methods of making the therapeutic layers within the bioresorbable sent are further disclosed. Sustained drug delivery reduces the risk of late and very late stent thrombosis.
• BIORESORBABLE, IMPLANTABLE DEVICE HAVING CONTROLLED DRUG DELIVERY
  申请人：Scanlon John James

  公开号：US20220031482A1

  公开（公告）日：2022-02-03

  A bioresorbable, implantable device having controlled drug delivery is disclosed herein. The bioresorbable, implantable device is configured as a film, a roll, a tube, and a stent. The bioresorbable, implantable device is configured to release an active ingredient (the “drug”) from the bioresorbable, implantable device when the bioresorbable, implantable device is implanted within a body. The bioresorbable, implantable device is configured to control the onset of the release of the drug, the sequence of drug delivery, and the duration of drug delivery by embedding the drug within at least one therapeutic layer positioned within bioresorbable, implantable device.